American College of Physicians recommends monotherapy with cognitive therapy or second-generation antidepressant for patients in acute phase of moderate-to-severe depression
Your search for major depressive disorder returned 126 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
In this review, authors focused on the psychiatric issues that often accompany migraine and the effects of botulinum toxin A on migraine.
However, expansion of telehealth yielded net increase in care for major depressive disorder, anxiety, and adjustment disorder
Electronic health records from 77 health care organizations in the US were evaluated for a risk for endocarditis among patients with opioid use disorder or cocaine use disorder on the basis of contracting COVID-19.
Researchers sought to evaluate the efficacy and safety of galcanezumab in patients with migraine in Japan.
Investigators from the Veteran’s Affairs Center for Innovation to Implementation and Stanford University searched publication databases through June 2022 for observational studies about methamphetamine-associated heart failure.
Deep learning, multidiagnostic model shows high accuracy before clinical examination
Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.
Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.
Being married, having a confidant associated with better mental health with COPD
Researchers measured associations between trauma and child psychiatric disorders in a birth cohort in Brazil.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
A team of investigators evaluated the prevalence of noncancer-related pain conditions among adult individuals with attention-deficit/hyperactivity disorder.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Adults with major depressive disorder and a history of childhood trauma can still benefit from recommended depression treatments.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.
Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
As people living with HIV begin to age, their risk of developing HIV-associated cognitive decline increases. A specific training program to help patients with HIV with speed of processing (SOP) may help stall those effects.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.